Stay informed with the latest litigation news. Explore now

IP Verse

Treating Infections With Ceftolozane/Tazobactam In Subjects Having Impaired Renal Function - EP3043797B1

EP3043797

MERCK SHARP & DOHME
Application Number
EP14842042A
Filing Date
Sep 9, 2014
Status
Opposition Rejected
Nov 25, 2022
Grant Date
Apr 8, 2020
External Links
Slate, Register, Google Patents
Similar Patents facing opposition
EP3165220B2
EP3616695B1
EP3283882B2

Bibliography

The patent EP3043797B1 was granted to Merck Sharp & Dohme on Apr 8, 2020 following the initial filing on Sep 9, 2014 under the application number EP14842042A . The current legal status of the patent is Opposition Rejected.

Patent Summary

Patent Family New

Patent Family

Patent Oppositions

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.

CompanyOpposition DateOpposition Status

Get instant alerts for new oppositions and patent status changes

LEDERER & KELLER PATENTANWALTE PARTNERSCHAFT MBBDec 21, 2020 -

Dossier Documents

The dossier documents provide a comprehensive record of the patent’s prosecution history, including filings, correspondence, and decisions made by patent offices. These documents are crucial for understanding the patent’s legal journey and any challenges it may have faced during examination. It also includes the oppositions documents filed against the patent.

  • Date

    Description

  • Get instant alerts for new documents